3.61
+0.03(+0.84%)
Currency In USD
Address
Building III
Langhorne, TX 78746
United States of America
Phone
512 614 1848
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
April 28, 2017
| Name | Title | Pay | Year Born |
| Mr. Matthew Pauls J.D., M.B.A. | Chairman & Chief Executive Officer | 979,000 | 1971 |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer | 91,889 | 1951 |
| Mr. Robert Matthew Lutz M.B.A. | Chief Operating Officer | 672,451 | 1969 |
| Mr. David L. Lowrance CPA | Chief Financial Officer, Chief Administrative Officer & Secretary | 673,291 | 1968 |
| Brian Maurer | Head of Clinical Operations | 0 | N/A |
| Dr. Yasmine Wasfi M.D., Ph.D. | Executive Vice President and Head of Clinical Development & Clinical Operations | 0 | N/A |
| Ms. Anne Erickson | Chief Business Officer | 0 | 1972 |
| Mr. Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs | 0 | N/A |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs | 0 | N/A |
| Ms. Kate McCabe J.D. | Chief Legal Officer | 0 | 1986 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.